13 C]Ala of PG to be 3.5 Å. The measured REDOR distance constraints position the C-terminus of the glycopeptide in the proximity of the L-Ala of the PG, suggesting that the C-terminus of the glycopeptide interacts near the L-Ala segment of the PG stem. In vivo REDOR measurements provided structural insight into how C-terminally modified glycopeptide antibiotics operate.
Nenriched eremomycin derivative with a C-terminal [
15 N]amide and [
15 N]Asn amide, was complexed with whole cells of Staphylococcus aureus grown in a defined medium containing L- [3- 13 C]Ala and D-[1- 13 C]Ala in the presence of alanine racemase inhibitor alaphosphin. 13 C]Ala to be 5.1 and 4.8 Å, respectively. These measurements also determined the distance from the C-terminal [ 15 N]amide of LCTA-1421 to the L- [3- 13 C]Ala of PG to be 3.5 Å. The measured REDOR distance constraints position the C-terminus of the glycopeptide in the proximity of the L-Ala of the PG, suggesting that the C-terminus of the glycopeptide interacts near the L-Ala segment of the PG stem. In vivo REDOR measurements provided structural insight into how C-terminally modified glycopeptide antibiotics operate. V ancomycin is a glycopeptide antibiotic exhibiting potent activities against almost all strains of Gram-positive cocci and bacilli. 1 In 1956, Eli Lilly and Company discovered vancomycin in soil samples collected from Borneo; the antibiotic was being produced by soil microbe Amycolatopsis orientalis. Since the discovery of vancomycin, researchers have identified ∼50 different glycopeptide antibiotic-producing organisms with more than 100 different natural glycopeptides. 2, 3 All glycopeptides have a heptapeptide core (aglycon) structure formed by heavily cross-linked amino acids through a series of phenolic oxidative couplings. The glycopeptides are classified into four types on the basis of their chemical structure (Supplementary Figure S1) . 4 Vancomycin is a Type I glycopeptide with methylated leucine and asparagine at the first and third positions of the aglycon, respectively. In Type II glycopeptides, such as avoparcin, the first and third residues are replaced by aromatic amino acids. Type III and IV glycopeptides also have aromatic amino acids at the first and third positions, but they are cross-linked by a phenolic−ether linkage. Ristocetin is an example of a Type III glycopeptide, with its aglycon structure modified by six sugar adducts.
Teicoplanin, a Type IV glycopeptide, has an aglycon core structure identical to that of Type III but differs by an acyl chain attached to the sugar moiety.
Glycopeptides inhibit peptidoglycan (PG) biosynthesis by binding to lipid II, a membrane-bound PG precursor. This behavior was discovered when vancomycin was added to cell extracts of Staphylococcus aureus inhibited the formation of the PG (Figure 1 ) and the incorporation of glycine into lipid II. 5 When vancomycin is added to whole cells of bacteria, cytoplasmic precursors accumulate (Park's nucleotide) and the cell wall becomes thinner. These results support the hypothesis that vancomycin inhibits transglycosylation by targeting lipid II. 6 By binding to lipid II, vancomycin effectively sequesters the lipid transporter C 55 , the limiting factor in PG biosynthesis, which is present only in a small number of copies per bacterium. The lipid transporter is regenerated from lipid II only during the transglycosylation step of PG biosynthesis.
Binding of vancomycin to D-Ala-D-Ala was first identified when vancomycin failed to inhibit in vitro PG polymerization of UDP-MurNac-tetrapeptide purified from the membrane fractions of Gaf fkya homari. 7 Because the UDP-MurNactetrapeptide lacked the terminal D-Ala found on the PGpentapeptide stem (Figure 1 Figure 2 shows the X-ray crystal structure of vancomycin bound to diacetyl-L-Lys-D-Ala-D-Ala 9 and the solution-state NMR structure of chloroeremomycin complexed with PG precursor analogue L-Ala-D-iso-Glu-L-Lys-D-Ala-D-Ala. 10 Both vancomycin and chloroeremomycin share an identical heptapeptide core structure that forms the D-Ala-D-Ala binding site. Five hydrogen bonds stabilize the D-Ala-D-Ala segment as it is attached to the aglycon structure (Figure 2, bottom) . (i) The first three H-bonds are located between the amide protons (NH2−NH4) and the carboxyl oxygen on the C-terminus of the D-Ala-D-Ala segment. (ii) A fourth bond is located between the carbonyl oxygen on the fourth residue of the aglycon (CO4) and an amide proton of the terminal D-Ala. (iii) A fifth bond is located between the amide proton of the seventh residue of the aglycon (NH7) and the carbonyl oxygen of the LLys. The hydrophobic interactions between the aromatic residues of the glycopeptide core structure and the methyl group of the alanines in the dipeptide are thought to further stabilize the drug-bound structure. In both X-ray crystal and solution-state NMR structures, the disaccharides of vancomycin and chloroeremomycin do not participate in D-Ala-D-Ala binding.
Structure and activity studies of glycopeptides and biochemical evidence suggest that in vivo glycopeptide−PG binding is far more complex than mere D-Ala-D-Ala dipeptide binding. 2, 11 Some of the evidence is listed here. greater. (2) The chlorine atom on the second amino acid of vancomycin improves the activity. The dechlorinated vancomycin (monodechlorovancomycin) is only half as active as vancomycin. (3) The removal of sugars from vancomcyin (deglycosylated vancomycin) does not affect D-Ala-D-Ala binding, but it reduces the activity by a factor of 5. The sugars on vancomycin have been attributed to the formation of a drug dimer, but in vivo glycopeptides are found as monomers, 12−16 which suggests that the sugars enhance the activity by facilitating PG binding through sugar−PG interactions. 15 (4) Methylated leucine, the first amino acid on vancomycin, is crucial for activity. The Edman degradation removal of leucine destroys the dipeptide binding affinity and its activity. (5) Asparagine, the third residue of vancomycin, does not participate in D-Ala-D-Ala binding but is required for its activity. 17 Replacing asparagine with glutamine (lengthening the side chain by one carbon) or replacing it with an aspartate (introducing negative charge) reduces the activity by 2-and 10-fold, respectively. Substitution of asparagine with isoasparte destroys the antimicrobial activity.
2,11 (6) Alkylation of the drug sugar by a hydrophobic side chain improves the activity. 18−21 (7) The carboxyl-terminal modifications of the glycopeptide improve the activity even though it is not involved in D-Ala-DAla binding. 22 In this study, we investigate in vivo glycopeptide−PG binding interactions using solid-state NMR. Unlike solution-state NMR and X-ray diffraction structures based on the drug bound to PG-mimicking peptides, solid-state NMR allows direct investigation of the glycopeptide−PG complex in intact whole cells of S. aureus. bound to the D-Ala-D-Ala segment of the PG stem in whole cells. We anticipated that the in situ aglycon structure of LCTA-1421 bound to the D-Ala-D-Ala segment of PG in the cell wall will be different from the solution-state NMR and X-ray diffraction structures based on the drug bound to a model peptide that suffers from the artifacts of drug dimerization and crystal lattice constraints, respectively. The in situ aglycon structure of LCTA-1421 bound to PG was inferred from the internuclear 13 C]Ala of the PG stem using rotational-echo doubleresonance (REDOR) NMR. 23, 24 The second probe, the C-terminal [
15 N]amide of LCTA-1421, was used to determine whether interaction of the glycopeptide with the non-D-Ala-D-Ala segment of the PG stem structure by measuring the 13 15 N]amide-carboxyeremomycin (LCTA-1421) was described by Solov'eva et al. 25 Briefly, eremomycin was treated with barium hydroxide at 37°C for 4 h to yield carboxyeremomycin. 17 Growth of Whole Cells of S. aureus. A starter culture of S. aureus (ATCC 6538P) was added (1% final volume) to a 1 L flask containing 250 mL of sterile S. aureus standard medium (SASM), which consists of L- [3- 13 C]Ala and D-[1-13 C]Ala in the presence of the alanine racemase inhibitor alaphosphin (5 mg/L). The detailed protocol for preparing SASM has been described elsewhere. 15, 16, 27 The cells were harvested at an optical density at 660 nm of 1.0, washed twice, and then resuspended in 10 mL of water containing 7.1 mg of LCTA-1421. After 10 min on ice, the LCTA-1421−bacterium complex was frozen using liquid N 2 and then lyophilized. The lyophilized sample weight was 250 mg.
Solid-State NMR Spectrometer and REDOR NMR Parameters. REDOR NMR experiments were performed on an 89 mm bore Oxford (Cambridge, England) superconducting solenoid at 4.7 T (200 MHz for 1 H), using a four-frequency transmission line probe with a Chemagnetics/Varian ceramic stator. The samples were contained in a 7.5 mm outside diameter zirconia rotor spinning at 5 kHz at room temperature. Radiofrequency pulses for 13 15 N, and 19 F. Proton−carbon and proton− nitrogen matched cross-polarization transfers were at 50 kHz for 2 ms. Proton dipolar decoupling during signal acquisition was 105 kHz. Standard XY-8 phase cycling 28 was used for all refocusing and dephasing pulses.
The REDOR NMR method recouples heteronuclear dipolar interactions under magic-angle spinning (MAS) 23, 24 to determine heteronuclear dipolar couplings and hence internuclear distances. REDOR NMR has been described elsewhere; 15, 16, 27 briefly, in the full-echo (S 0 ) spectrum, dipolar dephasing is refocused over a single rotor period by MAS. In the S spectrum, the spin part of the dipolar interaction prevented full refocusing via application of dephasing π pulses, which reduced the peak intensity for dipolar coupled spin pairs. The difference in signal intensity (ΔS = S 0 − S) for the observed spin ( 13 C or 15 N) is directly related to the heteronuclear dipolar coupling from which the corresponding distance to the dephasing spin is determined. The normalized REDOR difference (ΔS/S 0 ), based on the peak height measurements, is a direct measure of dipolar coupling, which was calculated using the modified Bessel function expressions given by Mueller et al. 29 and de la Caillerie and Fretigny 30 for an IS spin-1 / 2 pair. The error bar for each REDOR dephasing was determined on the basis of the maximal noise peak intensity with respect to the dephased peak intensity.
Molecular Dynamics Simulation of the PG−LCTA-1421 Complex. Molecular dynamics simulation of LCTA-1421 bound to the PG pentapeptide stem structure was performed without water molecules to focus on the drug− target binding interactions. The initial model was generated on the basis of the NMR structure of chloroeremomycin complexed to the PG stem structure (L-Ala-D-iso-Gln-L-Lys-DAla-D-Ala) (PDB entry 1GAC). The CHARMM General Force Field (CGenFF) 31 for the simulating system was generated using the online server ParamChem (https://cgenff. paramchem.org/). After a 20 ns molecular dynamics simulation, the following distance constraints were applied: (i) 3. 9 The methyl carbon of L- [3- 13 C]Ala, on the other hand, is exclusively dephased by the C-terminal [ 15 N]amide of LCTA-1421, based on earlier structural characterization of LCTA-1110 complexed to PG. 15 LCTA-1110 is a fluorinated analogue of LCTA-1421 with a p-fluorophenylpiperazinamide at the C-terminal position (Figure 4, top) .
Structural characterization of LCTA-1110 complexed to PG provided the first clue that the C-terminus of LCTA-1110 might be involved in binding to the non-D-Ala-D-Ala segment of the PG stem structure, 15 which led to the synthesis of LCTA-1421 for investigating the interaction. Supplementary Table S1 . The measured REDOR distances are used as constraints for the molecular dynamics simulation of LCTA-1421 complexed to the PG stem structure shown in Figure 6 .
Antimicrobial Activities of the Carboxyl-Terminally Modified Glycopeptide Antibiotics. Supplementary Table  S2 shows the minimal inhibitory concentrations (MICs) of vancomycin, eremomycin, LCTA-1421, and LCTA-1110 against vancomycin-susceptible and -resistant strains of Grampositive bacteria. The C-terminally modified glycopeptides, LCTA-1421 and LCTA-1110, exhibit mild improved activities across the board against vancomycin-susceptible Gram-positive bacteria, vancomycin intermediate-resistant S. aureus, and vancomycin-resistant E. faecium and E. faecalis.
■ DISCUSSION
The LCTA-1421 Asparagine Side Chain Functions as a "Flap". Structure−activity studies have shown that the asparagine is essential for the activities in Type I glycopeptides. 2, 11, 22 Schafer et al. 34 proposed that the vancomycin asparagine side chain functions as a gate to regulate access of the ligand to the binding cleft.
In an "open" conformation in the X-ray crystal structure of an asymmetric vancomycin dimer, the asparagine side chain swings out of the binding cleft with an acetate ion occupying the D-Ala-D-Ala binding site. In a "closed" conformation, the asparagine side chain swings into the binding cleft. 34 An X-ray crystal structure of vancomycin bound to diacetyl-L-Lys-D-Ala-D-Ala (Figure 2, left) also showed that the asparagine side chain swings out of the binding cleft to accommodate ligand binding. Loll et al. 35 proposed that the asparagine side chain functions as a "flap" in the absence of a ligand, acting as a ligand surrogate by occupying the binding site. The "flap" prevents the hydration of the ligand binding cavity, which is energetically favorable as the water molecules placed within a highly polarized binding pocket are thought to be difficult to remove for the ligand to bind.
It is unclear how critical the "flap" is for the glycopeptide activity. As shown in Supplementary Figure S1 , Type III and IV glycopeptides have aromatic residues at amino acid positions 1 and 3 that are cross-linked by a phenolic−ether linkage. This rigid macrocylic ring structure is incompatible with the proposed "flap" function in vancomycin, and furthermore, glycopeptide antibiotics of Types III and IV exhibit potent antimicrobial activities, even in the absence of the "flap", suggesting that asparagine's "flap" mechanism might not have a significant effect. Supplementary Table S3 . In an X-ray crystal structure, the asparagine side chain of vancomycin is positioned out of the D-Ala-D-Ala binding site; in contrast, solidstate NMR positions the asparagine side chain closer to the DAla-D-Ala binding pocket. We believe that the crystallization of vancomycin, forming a hexamer repeat unit, affects the conformation of the vancomycin−dipeptide structure. In comparison, solution-state NMR of the chloroeremomycin dimer determines that the corresponding N−C distances are 6.9 and 4.4 Å. 10 The solution-state NMR measurement agrees closely with REDOR NMR distance measurements of 5.1 and 4.8 Å (Figure 6 ). However, one caveat is that the solution NMR structure represents a chloroeremomycin bound to a model peptide mimicking PG as a dimer. We have found that glycopeptide antibiotics that readily form a dimer in solution 36−38 when complexed to whole cells of S. aureus are found as a monomer when bound to PG. 15, 16, 39 Even one of the strongest dimer-forming glycopeptides, oritavancin, is found as a monomer when complexed to the PG in whole cells of S. aureus. 16 Hence, distance constraints determined by REDOR NMR represent the in vivo glycopeptide conformation of monomeric PG binding in the cell wall of intact whole cells, without any effects from drug dimerization, PG mimic binding, or crystal lattice constraints.
We propose an alternative relationship between the asparagine side chain and the formation of the ligand binding site. The asparagine side chain does not directly form a hydrogen bond with D-Ala-D-Ala, but its proximity to the bound dipeptide strongly suggests a possible interaction with the Nmethylleucine (first amino acid of LCTA-1421). The interaction of the asparagine side chain with the Nmethylleucine can form a binding cavity that can stabilize dipeptide binding. Either Edman degradation of the Nmethylleucine in eremomycin (the parent compound of LCTA-1421) 40 or the replacement of asparagine with glutamine or aspartate can disrupt this action, thus decreasing antimicrobial activities. In the case of substitution of asparagine with isoaspartate, the D-Ala-D-Ala binding site is destroyed by rearrangement, forming CDP-I, which is devoid of antimicrobial activities. 41 REDOR distance constraints indicate that the asparagine and leucine side chains constitute a part of a hydrophobic pocket necessary for D-Ala-D-Ala binding. The proposed interaction between the asparagine and N-methylleucine in the presence of dipeptide will require further investigation.
The Table S2 ).
In conclusion, glycopeptide antibiotics exhibit potent antibacterial activities by inhibiting PG biosynthesis in Gram- 
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